科伦博泰生物-B(06990)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06990 科伦博泰生物-B

未开盘 03-24 16:08:20

421.000

+23.400

+5.89%

最高427.000	最低395.400	成交量64.45万
今开405.800	昨收397.600	日振幅7.95%
总市值981.71亿	流通市值685.26亿	总股本2.33亿
成交额2.66亿	换手率0.40%	流通股本1.63亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06990","market":"HK","secType":"STK","nameCN":"科伦博泰生物-B","latestPrice":421,"timestamp":1774339700007,"preClose":397.6,"halted":0,"volume":644532,"delay":0,"changeRate":0.05885311871227358,"floatShares":162769979,"shares":233185969,"eps":-1.203559,"marketStatus":"未开盘","change":23.4,"latestTime":"03-24 16:08:20","open":405.8,"high":427,"low":395.4,"amount":265996618,"amplitude":0.079477,"askPrice":421,"askSize":900,"bidPrice":420.6,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-3.508831,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774402200000},"marketStatusCode":0,"adr":0,"listingDate":1689004800000,"exchange":"SEHK","adjPreClose":397.6,"openAndCloseTimeList":[[1774315800000,1774324800000],[1774328400000,1774339200000]],"volumeRatio":1.1049777936296243,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06990","defaultTab":"news","newsList":[{"id":"2621065283","title":"高盛重申“买入”科伦博泰生物-B(06990)：芦康沙妥珠单抗OS数据表现突出 公司增长潜力持续释放","url":"https://stock-news.laohu8.com/highlight/detail?id=2621065283","media":"智通财经","labels":["dataReport"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621065283?lang=zh_cn&edition=full","pubTime":"2026-03-24 18:30","pubTimestamp":1774348218,"startTime":"0","endTime":"0","summary":"高盛认为，其核心产品芦康沙妥珠单抗已成为公司增长的核心驱动力。2026年，随着产品已纳入国家医保目录，公司预计芦康沙妥珠单抗的销售将实现大幅增长，并有望在已获批适应症中成为医生首选，这部分预计将贡献超过80%的收入。此前，公司已宣布芦康沙妥珠单抗联合帕博利珠单抗一线治疗PD-L1阳性非小细胞肺癌的III期研究已达到主要终点，进一步验证这一ADC+IO联用组合的临床价值。RDC的全球热度正在升温，科伦博泰已经提前完成卡位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418118.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"高盛重申“买入”科伦博泰生物-B(06990)：芦康沙妥珠单抗OS数据表现突出 公司增长潜力持续释放","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE0004091025.USD","LU0061475181.USD","BK4552","LU2750360997.AUD","IE00BSNM7G36.USD","06990","LU1668664300.SGD","LU0345770993.USD","LU1791807156.HKD","IE00BFXG1179.USD","LU1868836591.USD","LU2237443465.HKD","LU1868836914.USD","LU2750360641.GBP","BK4516","BK4533","LU2471134523.USD","LU0096364046.USD","LU2237443895.HKD","LU0251142724.SGD","BK4550","BK4127","LU0742534661.SGD","LU1804176565.USD","BK4585","IE0004086264.USD","LU0106831901.USD","LU0345770308.USD","IE00B19Z3581.USD","BK1161","IE0002270589.USD","LU2237443549.SGD","LU2237438978.USD","LU2265009873.SGD","LU2471134879.HKD","LU0196878994.USD","GSX","LU2237443622.USD","BK4588","LU2237443382.USD","LU1868837136.USD","LU1894683264.USD","LU0048573561.USD","LU1868836757.USD","LU0251131958.USD","IE00B19Z3B42.SGD","LU2237443978.SGD","LU2471134796.USD","IE0034235188.USD","LU1894683348.USD"],"gpt_icon":0},{"id":"2621057905","title":"科伦博泰生物-B(06990)： SKB103新药临床试验申请获国家药品监督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2621057905","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621057905?lang=zh_cn&edition=full","pubTime":"2026-03-24 16:48","pubTimestamp":1774342081,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦博泰生物-B 发布公告，本公司自主研发的新型靶向肿瘤相关抗原及免疫肿瘤学抗原的双特异性抗体偶联药物  SKB103的新药临床试验申请已获国家药品监督管理局 药品审评中心批准，用于治疗晚期实体瘤。这是本公司首个进入临床阶段的TAA-PD-L1 bsADC，也是继SKB571之后第二款进入临床阶段的用于肿瘤治疗的bsADC。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"科伦博泰生物-B(06990)： SKB103新药临床试验申请获国家药品监督管理局批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06990","LU0196878994.USD","BK1161"],"gpt_icon":0},{"id":"1125512630","title":"科伦博泰生物-B SKB103新药临床试验申请获中国国家药监局批准用于晚期实体瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=1125512630","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125512630?lang=zh_cn&edition=full","pubTime":"2026-03-24 16:47","pubTimestamp":1774342031,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B宣布，其创新药物SKB103的新药临床试验申请已正式获得中国国家药品监督管理局批准，将针对晚期实体瘤开展临床研究。此次获批标志着该药物在肿瘤治疗领域迈出关键一步，为后续研发奠定了重要基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06990","LU0196878994.USD"],"gpt_icon":0},{"id":"2621059310","title":"港股异动 | TSLP抗体疗法I期临床研究结果发表 科伦博泰生物-B(06990)涨超7% 和铂医药-B(02142)涨超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621059310","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621059310?lang=zh_cn&edition=full","pubTime":"2026-03-24 15:02","pubTimestamp":1774335720,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科伦博泰生物-B、和铂医药-B午后涨幅扩大。截至发稿，科伦博泰生物涨7.34%，报426.8港元；和铂医药涨4.65%，报11.7港元。消息面上，3月23日，和铂医药宣布，HBM9378首次人体1期临床试验结果已在线发表于同行评议期刊Drug Design, Development and Therapy。公开资料显示，HBM9378由和铂医药与科伦博泰联合开发，双方共同享有其全球权益。2025年1月，和铂医药及科伦博泰与Windward Bio签订战略合作，授予后者在全球范围内对该抗体进行研究、开发、生产和商业化的独家权益。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417947.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1161","02142","06990","BK4585","LU0196878994.USD","VXUS","BK1574","BK4588"],"gpt_icon":0},{"id":"2621037914","title":"大行评级丨高盛：下调科伦博泰生物-B目标价至526.49港元，下调盈测","url":"https://stock-news.laohu8.com/highlight/detail?id=2621037914","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621037914?lang=zh_cn&edition=full","pubTime":"2026-03-24 11:37","pubTimestamp":1774323421,"startTime":"0","endTime":"0","summary":"高盛发表研报指，科伦博泰生物-B去年下半年收入为11亿元，高于该行及市场预期，主要由授权收入按年增长79%带动；产品销售按半年跌25%，则逊预期，主要由于核心产品sac-TMT在2025年主要以自费形式销售，患者可及性受限，以及纳入国家医保目录后价格调整的渠道返点影响。\r\n\r\n　　管理层预期今年sac-TMT销售将倍增，目标成为医保目录内各个适应症的首选药物，占销售逾80%。该行将2026及2027年的每股盈利预测，由3.43及8.81元，下调至1.39及7.32元，以反映去年下半年业绩表现，及近期药物销售预测下调等；目标价由531.69港元降至526.49港元，维持“买入”评级。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260324/32093341.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["06990"],"gpt_icon":0},{"id":"2621032469","title":"大行评级丨瑞银：下调科伦博泰生物-B目标价至578港元，重申“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2621032469","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621032469?lang=zh_cn&edition=full","pubTime":"2026-03-24 11:07","pubTimestamp":1774321622,"startTime":"0","endTime":"0","summary":"瑞银发表研报指，科伦博泰生物-B去年下半年收入11亿元，按年升101%，符合该行及市场预期；净亏损2.37亿元，好过该行及市场预期；毛利率达74%，较2024年的66%及2025上半年的69%有所提升，主要受产品销售占比提升带动。因应该业绩，该行将2026及2027年sac-TMT销售预测下调至14亿元及26亿元，但上调授权收入预测，因今年更多第三期临床数据释出后或有潜在的里程碑付款；重申“买入”评级，目标价由593港元下调至578港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260324/32093225.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["06990"],"gpt_icon":0},{"id":"1188074054","title":"科伦博泰生物-B公布2025年度业绩：多款产品成功上市，梯队化管线蓄势待发","url":"https://stock-news.laohu8.com/highlight/detail?id=1188074054","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188074054?lang=zh_cn&edition=full","pubTime":"2026-03-24 10:32","pubTimestamp":1774319536,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B（股票代码：06990）正式披露了其2025年度的财务与业务进展。报告期内，公司成功实现了多款创新产品的商业化上市，标志着其研发成果进入收获期。与此同时，公司构建的梯队化产品管线布局完善，后续增长动力充足，展现出强劲的发展潜力，为未来的持续飞跃奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"1172232004","title":"异动解读 | 瑞银重申“买入”评级，科伦博泰生物-B盘中大涨5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=1172232004","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172232004?lang=zh_cn&edition=full","pubTime":"2026-03-24 10:26","pubTimestamp":1774319198,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B今日盘中大涨5.03%，引起了市场的广泛关注。消息面上，瑞银发表研究报告指出，科伦博泰生物-B去年下半年收入同比增长101%，符合预期；净亏损好于预期；毛利率提升至74%。尽管瑞银下调了其目标价及部分盈利预测，但报告重申了“买入”评级，这增强了市场对公司基本面的信心。报告显示，公司毛利率的提升主要受产品销售占比提高带动。瑞银预计，随着今年更多第三期临床数据释出，公司可能获得潜在的里程碑付款，从而带来授权收入。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["06990"],"gpt_icon":0},{"id":"2621721247","title":"ADC一哥，扣动新一轮增长扳机","url":"https://stock-news.laohu8.com/highlight/detail?id=2621721247","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621721247?lang=zh_cn&edition=full","pubTime":"2026-03-23 18:22","pubTimestamp":1774261341,"startTime":"0","endTime":"0","summary":"结合其成熟的“端到端”药物开发能力及经过市场验证的商业化路径，公司已悄然扣动新一轮的增长扳机。过去一年多来，芦康沙妥珠单抗获批了4项适应症，一举囊括了肺癌、乳腺癌两大癌种。比如，在备受瞩目的RDC领域，科伦博泰的SKB107在去年7月启动了一项治疗晚期实体瘤骨转移患者的I期临床。在ADC领域完成体系化的跨周期布局之后，科伦博泰正依托底层的创新势能，稳步向综合型、全面型治疗领域延伸。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417474.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4080","BK4231","ADC","06990","BK1161","LU0196878994.USD"],"gpt_icon":0},{"id":"2621772504","title":"科伦博泰生物-B(06990)发布年度业绩，收入20.58亿元 同比增加6.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621772504","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621772504?lang=zh_cn&edition=full","pubTime":"2026-03-23 18:10","pubTimestamp":1774260654,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦博泰生物-B 发布截至2025年12月31日止年度业绩，该公司取得收入人民币20.58亿元，同比增加6.46%;本公司权益股东应占年度亏损人民币3.82亿元;研发开支人民币13.2亿元，同比增加9.41%;每股亏损人民币1.66元。公告称，收入增加乃主要由于药品销售增加而贡献人民币5.43亿元的收入。公司的三种商业化产品，即sac-TMT(佳泰莱)、塔戈利单抗(科泰莱)及西妥昔单抗N01(达泰莱)首次成功入选《国家医保药品目录》，该目录自2026年1月1日起正式生效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417450.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"2620203185","title":"【券商聚焦】中国银河：“十五五”首次将生物医药列为国家新兴支柱产业，持续发力研发创新","url":"https://stock-news.laohu8.com/highlight/detail?id=2620203185","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620203185?lang=zh_cn&edition=full","pubTime":"2026-03-20 09:23","pubTimestamp":1773969824,"startTime":"0","endTime":"0","summary":"“十四五”规划重点关注医药创新产品产业化、医药产业化技术攻关、疫苗和短缺药品供应保障、产品质量升级、医药工业绿色低碳等五大工程，成效斐然，中国创新药获批上市数量由2015年的11款提升至2024年的92款，2024年共有22款国产化药和17款国产生物药获批上市，国产创新药占比提升至42%。“十五五”规划提出健全医疗、医保、医药协同发展和治理机制，生物医药产业首次被列为国家“新兴支柱产业”，战略定位进一步提升。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1976888","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0561508036.HKD","LU0708995583.HKD","SG9999014674.SGD","BK4585","LU1969619763.USD","02359","06881","02268","399441","LU0417516571.SGD","LU0307460666.USD","LU0348767384.USD","06990","LU1770034418.SGD","LU2778985437.USD","HK0000306685.HKD","XBI","LU0052750758.USD","HK0000320223.HKD","LU2242644610.SGD","LU2476274720.SGD","BK1147","BK1161","BK4581","BK1588","IE00B543WZ88.USD","LU2125910500.SGD","LU0348825331.USD","02696","LU0348766576.USD","BK4588","601881","BK1564","LU2328871848.SGD","LU0348735423.USD","LU2476274308.USD","09995","LU0540923850.HKD","09926","HK0000306701.USD","BK1141","06160","161726","LU2045819591.USD","LU0196878994.USD","LU0588546209.SGD","LU1720050803.USD","02162","BK0276"],"gpt_icon":0},{"id":"2620225732","title":"科伦博泰生物-B(06990)：核心产品芦康沙妥珠单抗(sac-TMT)于2025年欧洲肺癌大会上公布的研究成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2620225732","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620225732?lang=zh_cn&edition=full","pubTime":"2026-03-18 22:46","pubTimestamp":1773845187,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦博泰生物-B 发布公告，本公司靶向人滋养细胞表面抗原2抗体偶联药物芦康沙妥珠单抗(佳泰莱)关键临床研究的总生存期最终分析结果将在于当地时间3月25日至28日在丹麦哥本哈根举行的2026年欧洲肺癌大会的小型口头报告专场公布。基于这一积极结果，芦康沙妥珠单抗获国家药品监督管理局批准此适应症，该适应症已被纳入国家医保目录。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415655.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06990","LU0196878994.USD"],"gpt_icon":0},{"id":"2618929907","title":"每日卖空追踪 | 科伦博泰生物-B 03月11日卖空量成交5.25万股，卖空比例为14.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618929907","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618929907?lang=zh_cn&edition=full","pubTime":"2026-03-11 16:30","pubTimestamp":1773217838,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B北京时间03月11日，跌1.79%，卖空量成交5.25万股，较上一交易日减少62.15%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311163603a6b796e8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311163603a6b796e8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"2618516049","title":"科伦博泰生物-B(06990)与科伦嘉讯订立2026年辅助性市场管理服务框架协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2618516049","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618516049?lang=zh_cn&edition=full","pubTime":"2026-03-10 22:44","pubTimestamp":1773153858,"startTime":"0","endTime":"0","summary":"与科伦嘉讯集团订立2026年辅助性市场管理服务框架协议，将使本公司能够借助科伦嘉讯集团现有的资源对sac-TMT进行推广，从而更有效地达成列名目标。本公司认为，科伦嘉讯集团具备所需的行业知识，能够有效提供2026年辅助性市场管理服务框架协议项下的服务，且委聘科伦嘉讯集团可避免因委聘先前并无与本公司合作的新服务提供商而产生的前期成本。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412355.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0196878994.USD","06990","BK1161"],"gpt_icon":0},{"id":"1107973285","title":"港股异动 | 创新药概念股普涨，康方生物、科伦博泰生物涨超9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1107973285","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107973285?lang=zh_cn&edition=full","pubTime":"2026-03-10 09:58","pubTimestamp":1773107886,"startTime":"0","endTime":"0","summary":"3月10日，创新药概念股走强，$康方生物(09926)$、$科伦博泰(06990)$生物涨超9%，$三生制药(01530)$、$亚盛医药(AAPG)$、$康诺亚(02162)$涨超5%，$海西新药(02637)$涨近4%","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3f44e86c3bddb2de2b4a93e8a962fb5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0634319403.HKD","06990","LU1961090484.USD","IE00B543WZ88.USD","LU2399975544.HKD","LU2778985437.USD","LU2476274308.USD","LU2476274720.SGD","LU2488822045.USD","BK4585","LU0348767384.USD","IE00B5MMRT66.SGD","LU0540923850.HKD","BK4588","LU1720050803.USD","LU0348784397.USD","09926","LU0348766576.USD","IE00BPRC5H50.USD","LU0348825331.USD","BK1574","LU0561508036.HKD","LU0348783233.USD","BK1161","LU0348735423.USD","LU0348827113.USD","LU0417516571.SGD","LU0417516902.SGD","LU0417516738.SGD","LU1794554557.SGD"],"gpt_icon":0},{"id":"2618471906","title":"科伦博泰生物-B：SKB575新药临床试验申请获国家药品监督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2618471906","media":"格隆汇资讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618471906?lang=zh_cn&edition=full","pubTime":"2026-03-09 16:36","pubTimestamp":1773045405,"startTime":"0","endTime":"0","summary":"格隆汇3月9日丨科伦博泰生物-B宣布，公司与和铂医药合作研发的靶向胸腺基质淋巴细胞生成素及一个未公开靶点的长效双特异性抗体SKB575的新药临床试验申请已获中国国家药品监督管理局批准，用于治疗特应性皮炎。SKB575/HBM7575经过工程化设计，具有延长的半衰期以及良好的可开发性，可实现皮下给药。根据公司与和铂医药之间的合作协议，SKB575/HBM7575由公司主导设计与全球范围内的开发及商业化，和铂医药共同参与该项目投资与开发并将按约定共享收益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309163702a45aeaeb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309163702a45aeaeb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06990","LU0196878994.USD","BK1161"],"gpt_icon":0},{"id":"2618647176","title":"每日卖空追踪 | 科伦博泰生物-B 03月09日卖空量成交2.84万股，卖空比例为6.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618647176","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618647176?lang=zh_cn&edition=full","pubTime":"2026-03-09 16:30","pubTimestamp":1773045039,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B北京时间03月09日，跌1.61%，卖空量成交2.84万股，较上一交易日减少80.32%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309163606a6b1c9b3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309163606a6b1c9b3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06990","LU0196878994.USD"],"gpt_icon":0},{"id":"2618647123","title":"科伦博泰生物-B盘中异动 早盘大幅下跌5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618647123","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618647123?lang=zh_cn&edition=full","pubTime":"2026-03-09 09:32","pubTimestamp":1773019941,"startTime":"0","endTime":"0","summary":"2026年03月09日早盘09时32分，科伦博泰生物-B股票出现波动，股价急速跳水5.02%。截至发稿，该股报366.800港元/股，成交量1.15万股，换手率0.01%，振幅2.38%。科伦博泰生物-B股票所在的生物技术行业中，整体跌幅为2.10%。科伦博泰生物-B公司简介：四川科伦博泰生物医药股份有限公司是一家主要从事创新药业务的研发、生产和销售的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309093221a6b083d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309093221a6b083d4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06990","BK1161","LU0196878994.USD"],"gpt_icon":0},{"id":"1191158198","title":"港股异动 | 创新药概念股走强，科伦博泰生物-B、歌礼制药-B涨超7%，恒瑞医药、康方生物涨超6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1191158198","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191158198?lang=zh_cn&edition=full","pubTime":"2026-03-05 10:32","pubTimestamp":1772677926,"startTime":"0","endTime":"0","summary":"3月5日，创新药概念股走强，$科伦博泰生物-B(06990)$、$歌礼制药-B(01672)$涨超7%，$恒瑞医药(01276)$、$康方生物(09926)$涨超6%","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"be7091872f1e44aea2b2c791b8b6184f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","LU2097828805.USD","LU1961090484.USD","LU0405327494.USD","LU2289578879.USD","LU2580892789.USD","BK0196","IE00B543WZ88.USD","LU0359201885.HKD","LU0348827113.USD","LU1997245177.USD","BK1161","BK1574","LU0196878994.USD","LU2476274308.USD","BK0188","LU2097828631.EUR","LU2476274720.SGD","BK1515","LU0359202008.SGD","BK4588","LU2148510915.USD","BK0183","01672","LU2328871848.SGD","LU0417516738.SGD","LU1720050803.USD","LU1146622755.USD","BK1191","LU0348783233.USD","LU1580142542.USD","LU0348825331.USD","LU1794554557.SGD","LU1969619763.USD","LU2399975544.HKD","LU2488822045.USD","LU2778985437.USD","LU2580892862.HKD","BK0028","LU0348767384.USD","BK0012","IE00B5MMRT66.SGD","LU1023057109.AUD","LU0634319403.HKD","LU1997245094.SGD","LU2097828474.EUR","LU2495084118.USD","LU2543165471.USD","LU0417516571.SGD","LU0348735423.USD","LU1064130708.USD","LU0561508036.HKD","LU1781817850.SGD","06990","LU0348784397.USD","LU0417516902.SGD","LU0540923850.HKD","BK4585","LU0359201612.USD","BK0060","LU1997244956.HKD","LU2097828557.USD","LU0348766576.USD","LU1064131003.USD","LU1655091616.SGD","LU1328615791.USD","LU1820825898.SGD","LU2097828714.EUR","09926","IE00BPRC5H50.USD","LU1255011170.USD","LU0405327148.USD"],"gpt_icon":0},{"id":"1118480043","title":"科伦博泰生物-B（06990）更新2026年2月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1118480043","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118480043?lang=zh_cn&edition=full","pubTime":"2026-03-04 17:01","pubTimestamp":1772614891,"startTime":"0","endTime":"0","summary":"四川科伦博泰生物医药股份有限公司（“科伦博泰生物-B”，股票代码：06990）于2026年3月4日发布2026年2月的股份变动月报表，报告期截止至2026年2月28日。\n公司披露的数据显示，截至2月底，注册股本维持人民币233,185,969元，各类股份数量与上月一致。其中，H股数量为162,769,979股，内资股数量为65,773,800股，非上市外资股数量为4,642,190股。报告期内，公司并无新增发行、购回或注销股份，亦未出现任何库藏股变动。\n公司确认已遵守香港联合交易所有限公司上市规则及相关法律法规的规定。公告由联席公司秘书周泽剑签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"gpt_icon":0}],"profile":{"websiteUrl":"http://kelun-biotech.com","stockEarnings":[{"period":"1week","weight":-0.0009},{"period":"1month","weight":0.0106},{"period":"3month","weight":0.0043},{"period":"6month","weight":-0.1713},{"period":"1year","weight":0.6155},{"period":"ytd","weight":0.0734}],"compareEarnings":[{"period":"1week","weight":-0.0311},{"period":"1month","weight":-0.0511},{"period":"3month","weight":-0.0293},{"period":"6month","weight":-0.0537},{"period":"1year","weight":0.0484},{"period":"ytd","weight":-0.0221}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"四川科伦博泰生物医药股份有限公司是一家主要从事新药业务的研发、生产和销售的中国公司。该公司主要从事肿瘤学、免疫学及其他治疗领域的创新药物的研发、制造及商业化。该公司的产品为抗体药物偶联物（ADC）SKB264及A166。该公司产品主要用于乳腺癌、非小细胞肺癌、胃肠道癌等非肿瘤疾病的治疗。","exchange":"SEHK","name":"科伦博泰生物-B","nameEN":"SKB BIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科伦博泰生物-B(06990)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科伦博泰生物-B(06990)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科伦博泰生物-B,06990,科伦博泰生物-B股票,科伦博泰生物-B股票老虎,科伦博泰生物-B股票老虎国际,科伦博泰生物-B行情,科伦博泰生物-B股票行情,科伦博泰生物-B股价,科伦博泰生物-B股市,科伦博泰生物-B股票价格,科伦博泰生物-B股票交易,科伦博泰生物-B股票购买,科伦博泰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科伦博泰生物-B(06990)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科伦博泰生物-B(06990)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}